The ABC and News Corp are bringing legal action to challenge warrants authorising controversial raids by Australian Federal Police on the headquarters of the public broadcaster and the home of political journalist Annika Smethurst.
Mortgage provider and Brisbane Broncos sponsor Firstmac has hit fintech giant Zip Co with a lawsuit for allegedly infringing its “Zip” trade mark.
Media companies facing defamation suits by a former youth centre detainee are liable for third-party comments posted on their Facebook pages, a judge has ruled in a groundbreaking decision.
The Western Australian parliament will this week introduce a new class actions regime modelled on the federal scheme, in a move the state Attorney-General says will enhance access to justice and improve efficiency.
The Australian Council of Trade Unions and seven other unions have launched legal action on behalf of 27,000 workers over an alleged “sham” bonus scheme designed to pressure staff into accepting a future enterprise agreement.
Dairy supplier Murray Goulburn has agreed to pay $42 million to settle one of two shareholder class actions over a 2016 profit forecast revision that sent the co-op’s unit price falling more than 40 per cent in five days.
A firm owned by solicitor Mark Elliot has launched an appeal challenging costs orders made against it in a stayed class action against winemaker Treasury Wine Estates.
Landowners above the Sydney Metro underground tunnel will be allowed to claim compensation before construction is complete, with a court also preparing to consider potential compensation for any reduced development potential.
Three shareholder class actions against RCR Tomlinson have been allowed to continued, setting up a class action beauty contest over who will lead the litigation against the failed engineering company.
Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
